Date: 2016-09-12
Type of information: Nomination
Compound:
Company: Oryzon Genomics (Spain)
Therapeutic area: Neurodegenerative diseases - Neuroinflammatory diseases
Type agreement: nomination
Action mechanism:
Disease: multiple sclerosis
Details: * On September 12, 2016, Oryzon Genomics announced that Dr. Xavier Montalban has also joined the Scientific
Advisory Board of the Company to help Oryzon’s scientists to explore the clinical potential of LSD1 inhibitors in the treatment of neuroinflammatory disorders like multiple sclerosis. Oryzon has a highly competitive and productive Epigenetics Platform, centered around the development of LSD1 inhibitors, with a first drug currently in Phase IIA in acute leukemia that validates the platform scientifically and clinically. This Platform has so far produced two compounds in clinical development with multiple indication opportunities for both drugs. Oryzon’s LSD1 drugs are pioneering the Histone demethylases field with its forerunner oncologic drug, ORY-1001, licensed to Roche in 2014, and ORY- 2001 in Phase I in neurodegenerative disorders. In addition, Oryzon has nominated recently a third
epigenetic compound, also against LSD1, as preclinical candidate for a yet undisclosed non-oncological orphan indication.
Financial terms:
Latest news:
